Dr. Laura Soluri is a Farmingdale, New York based female podiatrist who is specialized in Podiatry. Active license number of Dr. Laura Soluri for Podiatry is N004598 in New York. Dr. Laura Soluri is qualified with a Doctor of Podiatric Medicine (D.P.M.) degree, licensed by the state, and practicing within the scope of that license. She diagnose and treat foot diseases and deformities. She can perform medical, surgical and other operative procedures, prescribe corrective devices and prescribe and administer drugs and physical therapy.
Complete Profile:
Dr. Laura Soluri speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Podiatrist
Credentials:
D.P.M.
Gender:
Female
Practice Address:
185 Merritts Rd, Farmingdale, New York, 11735-3254
Phone:
516-249-0600
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1568734127
NPI Enumeration Date:
29 Jan, 2012
NPI Last Update On:
29 Jan, 2012
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Laura Soluri are as mentioned below.
License Number
Specialization
State
Status
N004598
Podiatry
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
14 Fieldcrest Ln, Farmingdale, New York
Zip:
11735-2118
Phone Number:
516-249-0600
Fax Number:
--
Patients can reach Dr. Laura Soluri at 185 Merritts Rd, Farmingdale, New York or can call to book an appointment on 516-249-0600. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.